

32-3778: EXOSC10 Recombinant Protein

Uniprot ID : Q01780
Alternative Name : Exosome component 10, Polymyositis/scleroderma autoantigen 2, Autoantigen PM/Scl 2, Polymyositis/scleroderma autoantigen 100 kDa, PM/Scl-100, P100 polymyositis-scleroderma overlap syndrome-associated autoantigen, EXOSC10, PMSCL, PMSCL2, p2, p3, p4, R

Description

Source : Sf9 insect cells. EXOSC10 Human Recombinant produced in SF9 is a glycosylated, polypeptide chain having a molecular mass of 120 kDa. EXOSC10 is expressed with a -6xHis tag and purified by proprietary chromatographic techniques. EXOSC10 is a nucleolar protein and represents one crucial component of the so-called 'PM/Scl complex' or 'nuclear exosome', which is an RNA-processing complex consisting of a number of exoribonucleases (not to be confused with certain multivesicular bodies which are shed by cultured cells into the culture fluid and are also called exosomes). Autoantibodies against EXOSC10 occur in patients suffering from polymyositis, scleroderma or polymyositis/scleroderma overlap syndromes. While antibodies to other components of the exosome complex (PM/Scl 75, several Rrp proteins) can be found in some sera, practically all patients with autoantibodies against the PM/Scl complex are positive for EXOSC10 antibodies, making this specificity an important marker. The presence of EXOSC10 autoantibodies is a comparatively 'good' prognostic sign in polymyositis/scleroderma overlap syndrome unlike the poor prognosis seen when other myositis and systemic sclerosis specific autoantibodies are present.

Product Info

Amount : 20 µg
Purification : Greater than 70% as determined by SDS-PAGE.
Content : EXOSC10 is supplied at a concentration of 0.8mg/ml in 20mM HEPES, pH-7.5, 100mM NaCl, 0.01mM EDTA, 0.02% SDS.
Storage condition : Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Avoid multiple freeze-thaw cycles.
Amino Acid : mappstrepr visatsatks dgemvlpqfp dadsfvkfal gsvvavtkas gglpqfgdey 61 dfyrspgqf afcetqgdr lqcmsrvmqy hgcrsnikdr skvteledkf dlldandvi 121 lervgillde asgvnknqqp vlpaglvqpk tvvsswnrka aeygkkakse tfrllhakni 181 irpqlkrek idnsntpflp kifikpnaqk plpqalsker rerpqdrped ldvppaladf 241 ihqqrqqve qdmfahpyqy elnhftpada vlqkppqly rpieetpCHF issldelvel 301 neklIncqef avdlehhsyr sflgtclmq istrtdfii dtlelrsdmy ilnesldpa 361 ivkvfhgads diewlqkdfg lyvnmfdth qaarlnlgr hslhdllkly cnvdsnkqyq 421 ladwriplp eemlsyardd thyllyiydk mrlemwergn gqpvlqvww qsrdiclkk 481 fikpiftdes ylelyrkqkk hlntqqltaf qlfawrdkt arredesygy vlpnhmmlki 541 aeelpkepqq iiaaccnpvpp lvrqqinemh lliqqaremp llksevaagv kksqplpsae 601 rlenvlfgph dcshappdgy piiptsgsvp vqkqaslfpd ekednllgtt cliatavitl 661 fnepsaedsk kgpltvqqk aqnimesfen pfrmfplslg hrapvsqaak fdpstkiyei 721 snrwklaqqq vqkdskeavk kkaaeqtaar eqakeackaa aeqaisvrqq vvlenaakkr 781 eratsdprtt eqkqekkrlik iskkpkdpep pekeftpydy sqsdfkafag nskskvssqf 841 dpnkqtpsgk kciaakkikq svgnksmsfp tgksdrgrfy nwpqr

